Find Dotinurad manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

KDMF

0

NDC API

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1285572-51-1, Fyu-981, Dotinurad [inn], (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2h)-yl)methanone, 305eb53128, (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone
Molecular Formula
C14H9Cl2NO4S
Molecular Weight
358.2  g/mol
InChI Key
VOFLAIHEELWYGO-UHFFFAOYSA-N
FDA UNII
305EB53128

Dotinurad
Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).
1 2D Structure

Dotinurad

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone
2.1.2 InChI
InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2
2.1.3 InChI Key
VOFLAIHEELWYGO-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
2.2 Other Identifiers
2.2.1 UNII
305EB53128
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone

2. Fyu-981

2.3.2 Depositor-Supplied Synonyms

1. 1285572-51-1

2. Fyu-981

3. Dotinurad [inn]

4. (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2h)-yl)methanone

5. 305eb53128

6. (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone

7. Urece

8. Methanone, (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2h)-benzothiazolyl)-

9. Urece (tn)

10. Dotinurad (jan/inn)

11. Dotinurad [jan]

12. Dotinurad [who-dd]

13. Fyu981

14. Chembl4594446

15. Schembl10322525

16. Gtpl11389

17. Unii-305eb53128

18. Ex-a5737

19. Bdbm50561689

20. Hy-109031

21. Cs-0030545

22. D11071

23. 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole

2.4 Create Date
2011-05-09
3 Chemical and Physical Properties
Molecular Weight 358.2 g/mol
Molecular Formula C14H9Cl2NO4S
XLogP32.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count1
Exact Mass356.9629343 g/mol
Monoisotopic Mass356.9629343 g/mol
Topological Polar Surface Area83.1 Ų
Heavy Atom Count22
Formal Charge0
Complexity538
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Uricosuric Agents

Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma. (See all compounds classified as Uricosuric Agents.)


USDMF

read-more
read-moreread-more

01

World Health Expo
Not Confirmed

01

World Health Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43344

Submission : 2025-12-24

Status : Active

Type : II

blank

02

World Health Expo
Not Confirmed

02

World Health Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43328

Submission : 2025-12-16

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

World Health Expo
Not Confirmed
arrow
arrow
World Health Expo
Not Confirmed

Dochinurad Manufacturing Only

Registration Number : 230MF10137

Registrant's Address : 6-11-24 Tsudanuma, Narashino City, Chiba Prefecture

Initial Date of Registration : 2018-10-01

Latest Date of Registration : 2018-10-01

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Dotinurad

Date of Issue : 2025-07-17

Valid Till : 2028-08-26

Written Confirmation Number : SD250073

Address of the Firm : No. 127, Qizhong Avenue, Qihe County, Dezhou City, Shandong Province, China

Shandong Loncom Pharmaceutical company banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

Flag China
Digital Content Digital Content

Dotinurad

About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...

Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming to global API standards, along with professional R&D and marketing teams, Hengkang’s operations span major pharmaceutical markets such as China, Europe, the CIS region, Japan, and South Korea. Hengkang has established long-term and stable relationships with nearly 70 countries overseas and hundreds of domestic enterprises. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Zhejiang Hengkang Pharmaceutical

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Dotinurad

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic Development Zone, Sh...

Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic Development Zone, Shandong Province, the company operates API pilot testing and production facilities meeting international standards. It runs 13 production lines for oral solid, oral liquid, and API manufacturing, and is expanding capabilities for injections, soft capsules, eye drops, topical medicines, and innovative drug R&D. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shandong Loncom Pharmaceutical company banner

03

Lewens Labs

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLewens Labs transforms healthcare with innovative, sustainable, and affordable pharmaceutical solutions worldwide.

Flag India
Digital Content Digital Content

Dotinurad

About the Company : Lewens Labs was established with a vision to transform the pharmaceutical industry, inspired by an award-winning engineering project that reduced the cost of Aceclofenac and receiv...

Lewens Labs was established with a vision to transform the pharmaceutical industry, inspired by an award-winning engineering project that reduced the cost of Aceclofenac and received four national accolades, including recognition from the Consultancy Development Center, GOI. The company remains committed to delivering high-quality, affordable, and sustainable pharmaceutical solutions through innovation beyond conventional chemistry and engineering, creating long-term value for healthcare and the scientific community. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

04

World Health Expo
Not Confirmed
arrow
arrow
World Health Expo
Not Confirmed

Dotinurad

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank

05

World Health Expo
Not Confirmed
arrow
arrow
World Health Expo
Not Confirmed

Dotinurad

About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...

Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry research/discovery fields. Excenen PharmaTech is dedicated to serve the pharmaceutical, scientific research and development industries for 10 years. During the past 10 years we supplied building blocks, small molecules, inhitbitors to world's leading companies like Janssen (Johnson&Johnson), Gilead, Abbvie..., Universities like Duke University, University of Chicago, University of Barcelona, University of Pécs etc.
blank

06

World Health Expo
Not Confirmed
arrow
arrow
World Health Expo
Not Confirmed

Dotinurad

About the Company : Guangzhou Green Cross Pharmaceutical is a leading Chinese manufacturer of amino acid injection formulations and a full-service provider of high-end parenteral nutrition and generic...

Guangzhou Green Cross Pharmaceutical is a leading Chinese manufacturer of amino acid injection formulations and a full-service provider of high-end parenteral nutrition and generic drugs. Among the first GMP-certified pharmaceutical companies in China, we have grown into a comprehensive group with integrated R&D, production, and sales. Our operations include one R&D center and five manufacturing bases for APIs and formulations.
blank

07

World Health Expo
Not Confirmed
arrow
arrow
World Health Expo
Not Confirmed

Dotinurad

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
blank

08

World Health Expo
Not Confirmed
arrow
arrow
World Health Expo
Not Confirmed

Dotinurad

About the Company : Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd. is a manufacturer specializing in targeted anticancer drug research and is devoted to researching, manufacturing and marketing...

Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd. is a manufacturer specializing in targeted anticancer drug research and is devoted to researching, manufacturing and marketing medical raw materials. The company's main products are crizotinib, afatinib, Capmatinib, Aloitinib, Sorafenib, Ibrutinib, Lenvatinib and many other kinds of TINI API.and intermediates Tianyuan pharmaceutical company in Zhangjiang Eastern has built 500 square meters of pilot laboratories, equipped with two sets of 50L glass reactor, four sets of 100L double reactor, six sets of 50L rotary evaporator and matching heating and cooling equipment.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.


Lead Product(s): Dotinurad,Allopurinol

Therapeutic Area: Rheumatology Brand Name: FYU-981

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Novo Holdings

Deal Size: $205.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing September 30, 2025

blank

01

World Health Expo
Not Confirmed
World Health Expo
Not Confirmed

Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.

Product Name : FYU-981

Product Type : Miscellaneous

Upfront Cash : Undisclosed

September 30, 2025

blank
  • Development Update

Details:

Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 28, 2025

blank

02

Crystalys Therapeutics

Country
arrow
World Health Expo
Not Confirmed

Crystalys Therapeutics

Country
arrow
World Health Expo
Not Confirmed

Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 28, 2025

blank
  • Development Update

Details:

Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 28, 2025

blank

03

Crystalys Therapeutics

Country
arrow
World Health Expo
Not Confirmed

Crystalys Therapeutics

Country
arrow
World Health Expo
Not Confirmed

Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 28, 2025

blank

Details:

Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Urece

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 08, 2024

blank

04

Eisai

Japan
arrow
World Health Expo
Not Confirmed

Eisai

Japan
arrow
World Health Expo
Not Confirmed

Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.

Product Name : Urece

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 08, 2024

blank

Details:

Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.


Lead Product(s): Dontinurad,Dotinurad,Allopurinol

Therapeutic Area: Rheumatology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 28, 2023

blank

05

World Health Expo
Not Confirmed
World Health Expo
Not Confirmed

Details : Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 28, 2023

blank

Details:

Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Urece

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Fortress Biotech

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 29, 2023

blank

06

World Health Expo
Not Confirmed
World Health Expo
Not Confirmed

Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.

Product Name : Urece

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 29, 2023

blank

Details:

Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabsorption in the kidneys.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Urece

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Urica Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 14, 2022

blank

07

Fuji Yakuhin

Japan
arrow
World Health Expo
Not Confirmed

Fuji Yakuhin

Japan
arrow
World Health Expo
Not Confirmed

Details : Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabso...

Product Name : Urece

Product Type : Miscellaneous

Upfront Cash : Undisclosed

December 14, 2022

blank

Details:

Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Urece

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Fuji Yakuhin

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 31, 2022

blank

08

World Health Expo
Not Confirmed
World Health Expo
Not Confirmed

Details : Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.

Product Name : Urece

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 31, 2022

blank

Details:

Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 14, 2022

blank

09

Eisai

Japan
arrow
World Health Expo
Not Confirmed

Eisai

Japan
arrow
World Health Expo
Not Confirmed

Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 14, 2022

blank

Details:

Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gout.


Lead Product(s): Dotinurad,Inapplicable

Therapeutic Area: Rheumatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 16, 2021

blank

10

Eisai

Japan
arrow
World Health Expo
Not Confirmed

Eisai

Japan
arrow
World Health Expo
Not Confirmed

Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gout.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 16, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1285572-51-1 / Dotinurad API manufacturers, exporters & distributors?

Dotinurad manufacturers, exporters & distributors 1

51

PharmaCompass offers a list of Dotinurad API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dotinurad manufacturer or Dotinurad supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dotinurad manufacturer or Dotinurad supplier.

PharmaCompass also assists you with knowing the Dotinurad API Price utilized in the formulation of products. Dotinurad API Price is not always fixed or binding as the Dotinurad Price is obtained through a variety of data sources. The Dotinurad Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Dotinurad

Synonyms

1285572-51-1, Fyu-981, Dotinurad [inn], (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2h)-yl)methanone, 305eb53128, (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone

Cas Number

1285572-51-1

Unique Ingredient Identifier (UNII)

305EB53128

About Dotinurad

Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).

Dotinurad Manufacturers

A Dotinurad manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dotinurad, including repackagers and relabelers. The FDA regulates Dotinurad manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dotinurad API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Dotinurad manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Dotinurad Suppliers

A Dotinurad supplier is an individual or a company that provides Dotinurad active pharmaceutical ingredient (API) or Dotinurad finished formulations upon request. The Dotinurad suppliers may include Dotinurad API manufacturers, exporters, distributors and traders.

click here to find a list of Dotinurad suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Dotinurad USDMF

A Dotinurad DMF (Drug Master File) is a document detailing the whole manufacturing process of Dotinurad active pharmaceutical ingredient (API) in detail. Different forms of Dotinurad DMFs exist exist since differing nations have different regulations, such as Dotinurad USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Dotinurad DMF submitted to regulatory agencies in the US is known as a USDMF. Dotinurad USDMF includes data on Dotinurad's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dotinurad USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Dotinurad suppliers with USDMF on PharmaCompass.

Dotinurad JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Dotinurad Drug Master File in Japan (Dotinurad JDMF) empowers Dotinurad API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Dotinurad JDMF during the approval evaluation for pharmaceutical products. At the time of Dotinurad JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Dotinurad suppliers with JDMF on PharmaCompass.

Dotinurad WC

A Dotinurad written confirmation (Dotinurad WC) is an official document issued by a regulatory agency to a Dotinurad manufacturer, verifying that the manufacturing facility of a Dotinurad active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dotinurad APIs or Dotinurad finished pharmaceutical products to another nation, regulatory agencies frequently require a Dotinurad WC (written confirmation) as part of the regulatory process.

click here to find a list of Dotinurad suppliers with Written Confirmation (WC) on PharmaCompass.

Dotinurad GMP

Dotinurad Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Dotinurad GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dotinurad GMP manufacturer or Dotinurad GMP API supplier for your needs.

Dotinurad CoA

A Dotinurad CoA (Certificate of Analysis) is a formal document that attests to Dotinurad's compliance with Dotinurad specifications and serves as a tool for batch-level quality control.

Dotinurad CoA mostly includes findings from lab analyses of a specific batch. For each Dotinurad CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Dotinurad may be tested according to a variety of international standards, such as European Pharmacopoeia (Dotinurad EP), Dotinurad JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dotinurad USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty